136 related articles for article (PubMed ID: 10680745)
21. 1-Methylnicotinamide protects against liver injury induced by concanavalin A via a prostacyclin-dependent mechanism: A possible involvement of IL-4 and TNF-α.
Jakubowski A; Sternak M; Jablonski K; Ciszek-Lenda M; Marcinkiewicz J; Chlopicki S
Int Immunopharmacol; 2016 Feb; 31():98-104. PubMed ID: 26709075
[TBL] [Abstract][Full Text] [Related]
22. Prevention of concanavalin A-induced mice hepatitis by molsidomine.
Okamoto T; Masuda Y; Kawasaki T
Int J Mol Med; 2001 Mar; 7(3):307-9. PubMed ID: 11179512
[TBL] [Abstract][Full Text] [Related]
23. A novel accessory role of neutrophils in concanavalin A-induced hepatitis.
Hatada S; Ohta T; Shiratsuchi Y; Hatano M; Kobayashi Y
Cell Immunol; 2005 Jan; 233(1):23-9. PubMed ID: 15893298
[TBL] [Abstract][Full Text] [Related]
24. Possible changes in expression of chemotaxin LECT2 mRNA in mouse liver after concanavalin A-induced hepatic injury.
Segawa Y; Itokazu Y; Inoue N; Saito T; Suzuki K
Biol Pharm Bull; 2001 Apr; 24(4):425-8. PubMed ID: 11305608
[TBL] [Abstract][Full Text] [Related]
25. Pretreatment with TCDD exacerbates liver injury from Concanavalin A: critical role for NK cells.
Fullerton AM; Roth RA; Ganey PE
Toxicol Sci; 2013 Nov; 136(1):72-85. PubMed ID: 23970800
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-15 prevents concanavalin A-induced liver injury in mice via NKT cell-dependent mechanism.
Li B; Sun R; Wei H; Gao B; Tian Z
Hepatology; 2006 Jun; 43(6):1211-9. PubMed ID: 16729307
[TBL] [Abstract][Full Text] [Related]
27. Effects of intravenous immunoglobulins on T-cell mediated, concanavalin A-induced hepatitis in mice.
Shirin H; Bruck R; Aeed H; Hershkoviz R; Lider O; Kenet G; Avni Y; Halpern Z
Liver; 1997 Dec; 17(6):275-80. PubMed ID: 9455732
[TBL] [Abstract][Full Text] [Related]
28. Glycyrrhizin protects mice from concanavalin A-induced hepatitis without affecting cytokine expression.
Okamoto T; Kanda T
Int J Mol Med; 1999 Aug; 4(2):149-52. PubMed ID: 10402481
[TBL] [Abstract][Full Text] [Related]
29. Ethyl pyruvate pretreatment attenuates concanavalin a-induced autoimmune hepatitis in mice.
Shen M; Lu J; Cheng P; Lin C; Dai W; Wang F; Wang C; Zhang Y; Chen K; Xu L; Zhou Y; Guo C
PLoS One; 2014; 9(2):e87977. PubMed ID: 24498418
[TBL] [Abstract][Full Text] [Related]
30. Galectin-3 deficiency prevents concanavalin A-induced hepatitis in mice.
Volarevic V; Milovanovic M; Ljujic B; Pejnovic N; Arsenijevic N; Nilsson U; Leffler H; Lukic ML
Hepatology; 2012 Jun; 55(6):1954-64. PubMed ID: 22213244
[TBL] [Abstract][Full Text] [Related]
31. Vasoactive intestinal peptide attenuates concanavalin A-mediated liver injury.
Luo Q; Wang Y; Feng D; Xu Y; Xu L
Eur J Pharmacol; 2009 Apr; 607(1-3):226-33. PubMed ID: 19222997
[TBL] [Abstract][Full Text] [Related]
32. Induction of thymocyte apoptosis by systemic administration of concanavalin A in mice: role of TNF-alpha, IFN-gamma and glucocorticoids.
Fayad R; Sennello JA; Kim SH; Pini M; Dinarello CA; Fantuzzi G
Eur J Immunol; 2005 Aug; 35(8):2304-12. PubMed ID: 16047339
[TBL] [Abstract][Full Text] [Related]
33. Requirement of IL-4 and liver NK1+ T cells for concanavalin A-induced hepatic injury in mice.
Toyabe S; Seki S; Iiai T; Takeda K; Shirai K; Watanabe H; Hiraide H; Uchiyama M; Abo T
J Immunol; 1997 Aug; 159(3):1537-42. PubMed ID: 9233653
[TBL] [Abstract][Full Text] [Related]
34. Differential involvement of IL-6 in the early and late phase of 1-methylnicotinamide (MNA) release in Concanavalin A-induced hepatitis.
Sternak M; Jakubowski A; Czarnowska E; Slominska EM; Smolenski RT; Szafarz M; Walczak M; Sitek B; Wojcik T; Jasztal A; Kaminski K; Chlopicki S
Int Immunopharmacol; 2015 Sep; 28(1):105-14. PubMed ID: 25976094
[TBL] [Abstract][Full Text] [Related]
35. Interleukin-11 reduces T-cell-dependent experimental liver injury in mice.
Bozza M; Bliss JL; Maylor R; Erickson J; Donnelly L; Bouchard P; Dorner AJ; Trepicchio WL
Hepatology; 1999 Dec; 30(6):1441-7. PubMed ID: 10573523
[TBL] [Abstract][Full Text] [Related]
36. CD44-deficient mice exhibit enhanced hepatitis after concanavalin A injection: evidence for involvement of CD44 in activation-induced cell death.
Chen D; McKallip RJ; Zeytun A; Do Y; Lombard C; Robertson JL; Mak TW; Nagarkatti PS; Nagarkatti M
J Immunol; 2001 May; 166(10):5889-97. PubMed ID: 11342603
[TBL] [Abstract][Full Text] [Related]
37. Protective role of IL-33/ST2 axis in Con A-induced hepatitis.
Volarevic V; Mitrovic M; Milovanovic M; Zelen I; Nikolic I; Mitrovic S; Pejnovic N; Arsenijevic N; Lukic ML
J Hepatol; 2012 Jan; 56(1):26-33. PubMed ID: 21703183
[TBL] [Abstract][Full Text] [Related]
38. IL-6, IFN-gamma and TNF-alpha production by liver-associated T cells and acute liver injury in rats administered concanavalin A.
Cao Q; Batey R; Pang G; Russell A; Clancy R
Immunol Cell Biol; 1998 Dec; 76(6):542-9. PubMed ID: 9893032
[TBL] [Abstract][Full Text] [Related]
39. Salvianolic acid A preconditioning confers protection against concanavalin A-induced liver injury through SIRT1-mediated repression of p66shc in mice.
Xu X; Hu Y; Zhai X; Lin M; Chen Z; Tian X; Zhang F; Gao D; Ma X; Lv L; Yao J
Toxicol Appl Pharmacol; 2013 Nov; 273(1):68-76. PubMed ID: 23993977
[TBL] [Abstract][Full Text] [Related]
40. Toll-like receptor 5 signaling restrains T-cell/natural killer T-cell activation and protects against concanavalin A-induced hepatic injury.
Wang L; Zhang W; Ge CH; Yin RH; Xiao Y; Zhan YQ; Yu M; Li CY; Ge ZQ; Yang XM
Hepatology; 2017 Jun; 65(6):2059-2073. PubMed ID: 28273362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
